New Rochelle, NY, May 17, 2016--Insulin pump therapy contributes to better blood glucose control in type 1 diabetes and, as pump technology continues to improve and become part of sensor-controlled feedback and artificial pancreas systems, essentially all patients would benefit from their capabilities according to a Commentary published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website until June 17, 2016.
In the Commentary "Is Pump Therapy for All with Type 1 Diabetes?" Darrell M. Wilson, MD, Stanford University, CA, compares and contrasts the advantages and limitations of diabetes management strategies including self-monitoring of blood glucose and multiple daily injections, continuous subcutaneous insulin infusion (insulin pumps), and fully closed-loop artificial pancreas systems that combine pump-based insulin delivery with integrated continuous glucose monitoring. The author provides his perspectives on the large knowledge base of published studies that have assessed the safety and effectiveness of different diabetes therapeutic approaches on glycemic control and hypoglycemic events.
"Insulin pump therapy has come farther along in the past 3 decades where pumps are much smaller and can be remotely operated by smartphones," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver. "Darrell highlights the importance of pump therapy in children and young adults and pathways leading on to closed-loop systems."
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world's leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Diabetes Technology & Therapeutics